The conference will focus on discussing the latest technologies in the preclinical, translational neuroscience space and also drawing the attention of the audience towards new innovations happening in translational neuroscience imaging. The conference further aims to bring in the experts from academia and industry together to discuss how to create new, more effective translational neuroscience drawing on novel technology and recent discoveries.

Paul Karila, CSO & Director, chronic pain research, will give a presentation on Oct 3 at 10.10 am titled:

How can we achieve better translation from in vitro to the clinic in neuroscience?

The talk will cover:

  • Bridging from rodent-based to human neuronal assays: How can we accelerate building in vitro models with better translational validity?
  • Opportunities and limitations of human models from iPS cells and native human nerve tissue.
  • Innovative co-culture assays for combined functional and morphological screening.

Visit event site

Neuroscience in Discovery & Development Congress takes place in Berlin, Germany on June 11-12. The meeting is part of Oxford Global’s R&D Europe Series and is co-located with the 20th Annual Drug Discovery Summit. The Congress will bring together key experts for presentations and case studies on the latest discoveries in CNS, along with patient stratification and biomarker development for neuroscience.

If you are interested in learning more about Cellectricon’s drug discovery services you are very welcome to reach out and schedule a meeting with us.

Visit event site

NDD Europe 2019 took place in Paris, France on May 22-23. The meeting was focused on neurodegenerative diseases and provided members of the drug development community with an opportunity to discuss how to overcome the translational challenges in the development of clinically disease-modifying therapeutics.

If you are interested in learning more about Cellectricon’s drug discovery services you are very welcome to reach out and schedule a meeting with us.

Visit event site

The 7th International Congress on Neuropathic Pain (NeuPSIG 2019) took place in London, UK on May 9-11, 2019. It is an international forum that provides the latest research and developments in understanding the mechanisms, assessment, prevention and treatment of neuropathic pain. This years’ meeting included two themes; diabetic neuropathic pain & chemotherapy-induced peripheral neuropathic pain.

If you did not attend the meeting, or missed the poster presentations, you are very welcome to reach out to learn more.

Recommended posters:

Visit event site

Cellectricon has appointed Dr. Thomas Nieland, Research Associate Professor at the Biomedical Engineering Department of Tufts University, to its scientific advisory board. Dr. Nieland brings extensive expertise in e.g. bioengineering and functional genomics as applied to neurodegenerative disease, neuropsychiatry and stem cell research to the advisory board.

Dr. Nieland obtained his PhD at the VU University of Amsterdam and currently holds the position of Research Associate Professor at the Biomedical Engineering Department of Tufts University in Boston, MA. Further, he also shares leadership of the Initiative of Neural Science, Disease and Engineering at Tufts University (INSciDE@Tufts). This is an interdisciplinary research center with the mission to accelerate the discovery of therapeutic solutions to brain disease, integrating technological innovations in biomedical engineering with stem cell biology and regenerative medicine.

At Tufts University, Dr. Nieland’s research is focused on human brain disease, in particular on identifying disease mechanisms, targets and drugs to treat autism spectrum disorders, Parkinson’s and Alzheimer’s disease. Previously, Dr. Nieland performed research at Harvard University, MIT, the Broad Institute of Harvard and MIT, Johns Hopkins University, Stanford University and Merck Research Laboratories.

“We are glad to welcome Thomas to our Scientific Advisory Board, where he will bring extensive disease area knowledge and be a key contributor in further enhancing Cellectricon’s CNS disease research.” said Cellectricon’s CEO, Dr. Mattias Karlsson.

AD/PD 2019, the 14th​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders took place in Lisbon, Portugal on March 26-31, 2019.

If you did not attend the meeting, or missed the poster presentations, you are very welcome to reach out to learn more.

Recommended posters:

Visit event site

Webinar Description:

Progressive neurodegeneration within interconnected brain regions is a common hallmark of several CNS diseases, such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). To be able to mimic the spreading of neuropathologies from brain region to brain region poses a particular challenge in CNS disease modelling. Additionally, the absence of high-capacity platforms, reflecting the complexity of progressive neuropathologies and that are suitable for intervention approaches, represent the current bottleneck in disease research and drug discovery campaigns.

To model the spreading of neuropathologies, we have developed a novel microfluidics platform which we combine with our previously established optical electrophysiology technology to create unique high throughput in vitro assays that reflect the hallmarks of the neurodegenerative disease cascade.

In this presentation, we will discuss the design concept and development of this new microfluidic assay platform including a technical validation of the platform. Furthermore, we will show how the platform can be used to model key aspects of Alzheimer´s disease associated neuropathology in primary neuronal cell cultures. We present future outlooks to apply our microfluidic assay platform for in vitro disease modelling for neuromuscular disorders, such ALS and muscular dystrophies, as well as for chronic pain research.

Tuesday March 19 @ 4 pm CET / 11 am EDT / 8 am PDT

Click here for more information and to register for the event.

 

Cellectricon, a collaborative services provider dedicated to advance drug discovery and research in the areas of chronic pain and neurodegenerative disease, is delighted to announce that we will participate in BonePainII, a European Innovative Training Network committed to promote frontline research, innovation and education within bone pain.

Millions of Europeans and beyond suffer from bone pain, which is a debilitating complication of e.g. many musculoskeletal disorders such as arthritis and bone metastasis. Even though the pain affects the quality of life of many people, research on bone pain has been limited. The BonePainII network has participants from six European countries and encompasses eight academic groups and four commercial companies all committed to creating an outstanding training program for 15 early stage researchers (ESRs) to elucidate the mechanisms of bone pain and develop new treatments.

“We are very pleased to be part of the BonePainII network and to be able to exchange knowledge with the neuroscientists and bone researchers within the network” said Cellectricon’s CEO, Dr Mattias Karlsson.

The 15 PhD students will obtain interdisciplinary, state-of-the-art training e.g. by secondments with industrial and academic partners within the network, including some of the foremost pain researchers in Europe. The project is funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 814244.

Cellectricon will collaborate with Karolinska Institutet to offer a 4-year PhD fellowship aimed to develop novel methods and assays for assessment of macrophage and bone cell-driven changes in nociceptor excitability in antibody-induced arthritis.

“In the PhD project we are driving, we are looking for a PhD candidate that will participate in the development of novel in vitro assays and technologies to mimic the interactions of a pathological bone environment with sensory neurons.” said Cellectricon’s CSO and Director of Chronic Pain research, Dr Paul Karila. “Example technologies that the student will use are microfluidic-based, compartmentalised chambers for creation of “disease in a dish” systems and high throughput assays. The methodologies developed in the PhD project, in addition to Cellectricon’s established models, will be used to investigate novel biomarkers of osteoarthritis (OA) pain and for drug screening to identify compounds that may be developed into therapeutics for patients suffering from bone pain.”

More information on the PhD position and how to apply. To learn more about the BonePainII network and partners, visit www.bonepain.eu